Navigation Links
Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
Date:3/17/2008

Potential to Develop Disease Treatments for Diabetic Kidney Disease and

Retinopathy, Each Multi-Billion-Dollar Drug Markets

JENKINTOWN, Pa., March 17 /PRNewswire/ -- Dynamis Therapeutics, Inc. announced the discovery of a new class of compounds that inhibit the production of RAGE, the Receptor for Advanced Glycation End Products (AGEs). Scientists expect that a RAGE inhibitor would be an important addition to the arsenal of drugs to treat diabetic kidney disease, retinopathy, microvascular disease, Alzheimer's, inflammatory diseases, some cancers, and aging.

A patent has been filed on the discovery.

A team of Dynamis Therapeutics' scientists significantly decreased kidney and retina RAGE in aged rats that were orally dosed with Dynamis Therapeutics' RAGE inhibitor for 32 weeks, as compared to non-treated rats. In addition, several other new compounds also inhibited RAGE in a variety of cells grown in culture.

In a parallel experiment, Dynamis Therapeutics' scientists increased the life span of mice by adding a RAGE inhibitor to their drinking water. The laboratory mice were divided into four groups: a control group treated only with water and three groups treated with varying doses of the RAGE inhibitor. The mice receiving the highest RAGE inhibitor dose lived, on average, 256 days longer than those receiving only water. Longevity increased proportionally with dosage strength.

Commented Dr. Annette Tobia, president and founder of Dynamis Therapeutics, Inc., "We are very excited about these results, since discovering RAGE inhibitors enables Dynamis Therapeutics to develop a treatment for diabetic kidney disease and blindness. Diabetes and its complications have become epidemic, not only in the United States, but worldwide. Retinopathy often leads to blindness. It would be a tremendous advance to eventually have a drug to treat such a serious disease."

Dynamis Therapeutics, Inc., located in Jenkintown, Pennsylvania (http://www.dynamis-therapeutics.com), develops products that treat chronic inflammatory conditions and accelerated aging diseases such as diabetic nephropathy and retinopathy.

Dynamis Therapeutics supports its research, in part, by marketing the MEG 21 product line of anti-aging and anti-wrinkling cosmetic skin care products to dermatologists, plastic surgeons, and aestheticians and by out-licensing the cosmetic applications of its breakthrough technology for fees and royalties.

Dynamis Therapeutics' technology is based on the discovery of an aging/inflammatory pathway that was made by its scientific founders while they were working at the Fox Chase Cancer Center in Philadelphia. The technology is exclusively licensed to Dynamis Therapeutics. Dynamis Therapeutics is presently preparing to file an IND with the FDA for a treatment for inflammation associated with dry eye.


'/>"/>
SOURCE Dynamis Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
2. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
3. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
4. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
5. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
6. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
7. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
8. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
9. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
10. Video: New Research Discovers Independent Brain Networks Control Human Walking
11. National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... -- External Defibrillators, Implantable Cardioverter Defibrillators, ... Cardiac Resynchronization Therapy Defibrillators (CRT-D), Manual External Defibrillators, ... The global defibrillators market is expected ... 2016-2020 and CAGR of 5.1% from 2020-2026. The ... of 5.2% from 2016 to 2026. The market ...
(Date:12/9/2016)... Research and Markets has announced the addition of the ... ... forecasts the global optical transceiver market to grow at a CAGR ... covers the present scenario and the growth prospects of the global ... report considers the revenue generated from the shipment of optical transceivers ...
(Date:12/9/2016)... Dec. 9, 2016 Mitsubishi Tanabe Pharma Corporation ... Representative Director, CEO: Dr. Masayuki Mitsuka ) has ... (ALS) given edaravone intravenously in 10-14 day cycles for ... by the ALS Functional Rating Scale-Revised (ALSFRS-R). The data ... on ALS/MND in Dublin, Ireland . ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Cable Network (PCN) during the summer of 2016. The program was made possible ... the United States Department of Health and Human Services Administration. The broadcast, ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio , founder ... national #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer ... Gives Back initiative, and we’re very pleased with the participation in every ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims to redefine ... are both engaging and easy to use. Coming off the heels of a ... today its plans to roll out new AI-powered self-service enhancements to help organizations ...
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
Breaking Medicine News(10 mins):